Fundraising Fox

Insitro

South San Francisco, US · Founded 2018 · Delaware corporation · 11 known investors

insitro.com ↗

insitro is a drug discovery and development company that uses machine learning and cellular data to identify therapeutic insights and accelerate the creation of new medicines. The company serves patients and pharmaceutical development by integrating in vitro lab data with human clinical data to decode biology and unlock transformative treatments.

AI & Machine LearningBiotechin /insitro@insitro

Founders & leadership

DK
Daphne KollerCEO & Founder
RN
Robert NelsenDirector
VP
Vijay PandeDirector
DV
Duane ValzGeneral Counsel
MR
Mary RozenmanChief Financial Officer

Investors · 11

Andreessen HorowitzMenlo Park · $500K – $50Mvia Vijay Pande · led
ARCH Venture PartnersChicago · $50K – $250Mvia Robert Nelsen · quoted
Foresite CapitalLarkspur
GV (Google Ventures)Mountain View · $250K – $50Mvia Krishna Yeshwant · led
HOF CapitalNew York · $25K – $15M
Bezos Expeditionsreported
BlackRockreportedWilmington
Casdin CapitalreportedNew York
CPP InvestmentsreportedToronto
TemasekreportedSingapore
Third Rock VenturesreportedBoston · $100K – $5M

Reported raises · per SEC filings

Form D private placements
▶$143.2MraisedMay 2020 · 26 investors · Biotechnology
Rule 506(b)
Exclusive: Machine Learning Company Insitro Raises $143 Million To Bridge Biology And AIforbes.com · May 2020
Officers, directors & promoters on the filing
  • Robert NelsenDirector
  • Vijay PandeDirector
  • Daphne KollerExecutive Officer, Director
  • Duane ValzExecutive Officer
  • Mary RozenmanExecutive Officer
Offering amount
$143.2M
Amount sold
$143.2M
First sale
Mar 2020
Incorporated
Corporation, Delaware, 2018
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

In the news